Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R) Meeting Abstract
| Authors: | Forde, P. M.; Nowak, A. K.; Hughes, B. G. M.; Kok, P. S.; Brown, C.; Sun, Z.; Anagnostou, V.; O'Byrne, K.; Yip, S.; Cook, A.; Lesterhuis, W. J.; Pavlakis, N.; Brahmer, J. R.; Kindler, H. L.; Tsao, A. S.; Zauderer, M. G.; Ramalingam, S. S.; Stockler, M. R. |
| Abstract Title: | Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS8599 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS8599 -- Meeting was also available virtually -- Source: Cinahl |
